BCRX Crosses Above Average Analyst Target
July 01, 2021 at 08:27 AM EDT
In recent trading, shares of BioCryst Pharmaceuticals Inc (BCRX) have crossed above the average analyst 12-month target price of $15.75, changing hands for $15.81/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..